drugset / Trial / NCT04059081

A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment

NCT04059081 ↗

Phase 2 Unknown 31 enrolled Deok-Hwan Yang Roche Pharma AG · collab
NaSingle-groupOpen-labelTreatment

Summary

This study is prospective, open-label, single arm observational study to assess efficacy of obinutuzumab plus chlorambucil (GC) chemotherapy in treatment naïve CLL, and prognostic impact of genetic alterations for CLL using NGS.

Timeline

Start
2019-07-09
Primary completion
2022-07-08
Completion
2022-07-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Obinutuzumab Monoclonal antibody 1000 mg Intravenous